Enumeral Biomedical Reports Third Quarter Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today provided a business update and announced its financial results for the quarter ended September 30, 2016.

“Over the last several weeks, we have begun to implement our plans to set Enumeral on a new course,” said Wael Fayad, Enumeral’s Chairman, Chief Executive Officer and President. “Innovation and collaboration are the foundation of our turnaround plans. Of course, we also recognize that we need to raise additional funding before the end of 2016 in order to advance our plans, and we are pursuing a range of potential transactions.”

Back to news